MedMira Invited to Appear Before House of Commons Sub-Committee on International Trade HALIFAX, May 3 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has been invited to appear before the House of Commons Sub-committee on International Trade to offer input on the Emerging Markets Strategy currently under development by International Trade Canada. MedMira, and other participants, were asked to provide feedback to the Committee based on their experiences and results in emerging international markets. Dr. James Smith, Vice President of Corporate Affairs and Giles Crouch, Vice President of Marketing & Business Development, will represent MedMira. "We're honoured to have the opportunity to provide our input on Canada's Emerging Markets Strategy," said Hermes Chan, president and COO of MedMira. "Canadian government support has been key to our successful business initiatives in China, and in other markets. In the global medical device market, many foreign governments and regulators view home government acknowledgement of the company as an indication of its quality and integrity." MedMira has successfully established its line of rapid diagnostic tests in key global markets, including China, the United States, Middle East, Caribbean and South Africa. MedMira is currently the only rapid, flow-through HIV test manufacturer to have products approved by regulatory bodies in Canada, the United States, and China. Chan added, "Government support is critical to companies bringing new products to the international marketplace. However, most government funding programs currently focus on research and development. We will be recommending to the Committee that funding programs be expanded to include regulatory and other qualifying processes to assist in the product commercialization phase." The Sub-Committee, through active consultations with leading businesses and organizations and a series of roundtable discussions, hopes to encourage more Canadian businesses to explore opportunities in key emerging markets. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout the Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail:

Copyright